The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Medtronic and Abbott have collaborated on a discount deal that makes the two stent giants preferred vendors for the costly medical devices at 135 U.S. hospitals.
University of Pennsylvania researchers compared three different carotid stents and found they are significantly similar to one another--and also highly effective at preventing stroke and death.
An international clinical trial concluded that using a two-stent technique to treat coronary bifurcation lesions with a large stenotic side branch didn't work any better than a provisional stenting approach.
Abbott finally won FDA approval for its MitraClip cardiac device after months of setbacks including an overseas safety warning, mixed study results and a cautious endorsement from a regulatory panel of experts worried about the product's effectiveness.
The Hatch-Waxman Act shook up the generic drugs business in 1984, and almost 30 years later, it's safe to say the law had its desired effect. About 84% of the 4 billion prescriptions written each year are for generic drugs, saving patients and government programs billions of dollars a year. In other words, generic drugs are big business. And with a slew of blockbuster brands now off patent, it's a big business with growing pains.
In its third-quarter earnings report, Abbott surprised investors with a sizable dividend boost, while Actelion assured shareholders it can deliver new profit streams before blockbuster Tracleer goes off patent in 2015. Baxter's report was a little less rosy, with earnings falling on acquisition costs.
Covidien has completed the spinout of its drug business and, as of July 1, is pretty much all about medical devices.
Bioresorbable cardiovascular stents are gaining momentum and drawing more investor interest. This time, the spotlight falls on Amaranth Medical, which is well underway with plans to raise a $25 million Series B funding round.
South Korean scientists believe they may have solved what causes very late stent thrombosis (blood clots) after drug-eluting or bare-metal stent implants. And their solution opens up a door to treating long-term stent patients and helping to boost their survival rates.